Inappropriate secretion of TSH was first described in 1960 in a patient with evidence of
hyperthyroidism and expanded sella on imaging. It was later found that a type of pituitary …

Peptide receptors involved in pathophysiological processes represent promising therapeutic
targets. Neuropeptide somatostatin (SST) is produced by specialized cells in a large number …

Object The aim of this study was to analyze clinicopathological characteristics and treatment
outcomes in a large single-center clinical series of cases of thyrotropin (TSH)–secreting …

Context: TSH-secreting pituitary adenomas (TSHomas) are rare. Epidemiological data are
scant and there are no reports on national incidence. Objective: The objective of the study …

Introduction In acromegaly the long-term exposure to high growth hormone (GH) and insulin-
like growth factor-1 (IGF-1) levels may result in specific complications in different human …

Normal or elevated thyrotropin (TSH) levels in hyperthyroid patients are characteristic of rare
TSH-secreting pituitary adenoma (TSH-oma), which is easily detectable by computed …

Purpose Thyrotropin-secreting pituitary adenomas (TSHomas) represent a rare subtype of
pituitary tumors. Neurosurgery (NCH) is still considered the first-line therapy. In this study we …

Preoperative control of hyperthyroidism in patients with TSH-secreting pituitary adenomas
(TSHoma) may avoid perioperative thyroid storm. Perioperative administration of octreotide …

Context First‐line therapy for thyrotropin‐secreting pituitary adenomas (TSHomas) is
neurosurgery, while medical treatment rests mainly on somatostatin analogues. Clinically …

Hyperthyroidism resulting from excessive thyroid stimulation by thyrotropin is rare. However,
since the advent of ultrasensitive TSH immunometric assays as first line test for thyroid …